9.84
-0.29(-2.86%)
Currency In USD
| Previous Close | 10.13 |
| Open | 9.92 |
| Day High | 10.19 |
| Day Low | 9.77 |
| 52-Week High | 19.73 |
| 52-Week Low | 5.41 |
| Volume | 1.1M |
| Average Volume | 1.71M |
| Market Cap | 854.08M |
| PE | -4.37 |
| EPS | -2.25 |
| Moving Average 50 Days | 8.32 |
| Moving Average 200 Days | 7.2 |
| Change | -0.29 |
If you invested $1000 in Kura Oncology, Inc. (KURA) 10 years ago, it would be worth $702.86 as of October 19, 2025 at a share price of $9.84. Whereas If you bought $1000 worth of Kura Oncology, Inc. (KURA) shares 5 years ago, it would be worth $296.39 as of October 19, 2025 at a share price of $9.84.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) Congress
GlobeNewswire Inc.
Yesterday at 7:23 AM GMT
FTI mechanism addresses innate and adaptive resistance pathways common to targeted oncology therapies Early clinical and preclinical data support darlifarnib’s potential to enhance clinical benefit of PI3Kα-, KRAS- and tyrosine kinase inhibitors 50%
Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
GlobeNewswire Inc.
Oct 01, 2025 11:01 AM GMT
– Expanding clinical experience and safety profile of ziftomenib support its evaluation in combination with approved FLT3 inhibitors in frontline AML – – FLT3 mutations occur in approximately 30% of newly diagnosed adult patients with AML and up to 5
Kura Oncology and Kyowa Kirin Announce First Patient Dosed in Pivotal Phase 3 KOMET-017 Trial of Ziftomenib for Frontline Acute Myeloid Leukemia (AML)
GlobeNewswire Inc.
Sep 29, 2025 8:01 PM GMT
– KOMET-017-IC trial of intensive chemotherapy combination will assess MRD negative CR and EFS as dual-primary endpoints to support potential U.S. accelerated and full approval – – KOMET-017-NIC trial of venetoclax / azacitidine combination will asse